The Innate Immune Receptor NLRX1 Functions as a Tumor Suppressor by Reducing Colon Tumorigenesis and Key Tumor-Promoting Signals

Cell Reports

Volumn 14, Issue 11, 2016, Pages 2562-2575

  Koblansky, A Alicia ^a,c   Truax, Agnieszka D ^a,c   Liu, Rongrong ^a,b   Montgomery, Stephanie A ^a,c   Ding, Shengli ^c   Wilson, Justin E ^a,c   Brickey, W June ^a,c   Mühlbauer, Marcus ^d   McFadden, Rita Marie T ^a   Hu, Peizhen ^e   Li, Zengshan ^e   Jobin, Christian ^d   Lund, Pauline Kay ^c   Ting, Jenny P Y ^a,c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 6 RECEPTOR ANTIBODY; MITOGEN ACTIVATED PROTEIN KINASE; NLRX1 PROTEIN; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; RECEPTOR ANTIBODY; STAT3 PROTEIN; UNCLASSIFIED DRUG; APC PROTEIN; AZOXYMETHANE; DEXTRAN SULFATE; MITOCHONDRIAL PROTEIN; MONOCLONAL ANTIBODY; NLRX1 PROTEIN, MOUSE; TOCILIZUMAB; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER MODEL; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; COLITIS; COLON CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; GENETIC MODEL; HUMAN; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR VOLUME; ANIMAL; C57BL MOUSE; CARCINOGENESIS; CHEMICALLY INDUCED; COLON; COLONIC NEOPLASMS; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; FLUORESCENCE MICROSCOPY; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; AZOXYMETHANE; BIOMARKERS, TUMOR; CARCINOGENESIS; COLON; COLONIC NEOPLASMS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; HUMANS; INTERLEUKIN-6; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSCOPY, FLUORESCENCE; MITOCHONDRIAL PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84962543071     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.02.064     Document Type: Article

References (65)

1. Abdul-Sater A.A., Saïd-Sadier N., Lam V.M., Singh B., Pettengill M.A., Soares F., Tattoli I., Lipinski S., Girardin S.E., Rosenstiel P., Ojcius D.M. Enhancement of reactive oxygen species production and chlamydial infection by the mitochondrial Nod-like family member NLRX1. J. Biol. Chem. 2010, 285:41637-41645.
2. Allen I.C., TeKippe E.M., Woodford R.M., Uronis J.M., Holl E.K., Rogers A.B., Herfarth H.H., Jobin C., Ting J.P. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J. Exp. Med. 2010, 207:1045-1056.
3. Allen I.C., Moore C.B., Schneider M., Lei Y., Davis B.K., Scull M.A., Gris D., Roney K.E., Zimmermann A.G., Bowzard J.B., et al. NLRX1 protein attenuates inflammatory responses to infection by interfering with the RIG-I-MAVS and TRAF6-NF-κB signaling pathways. Immunity 2011, 34:854-865.
4. Allen I.C., Wilson J.E., Schneider M., Lich J.D., Roberts R.A., Arthur J.C., Woodford R.M., Davis B.K., Uronis J.M., Herfarth H.H., et al. NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-κB signaling. Immunity 2012, 36:742-754.
5. Allocca M., Jovani M., Fiorino G., Schreiber S., Danese S. Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target. Curr. Drug Targets 2013, 14:1508-1521.
6. Anand P.K., Malireddi R.K., Lukens J.R., Vogel P., Bertin J., Lamkanfi M., Kanneganti T.D. NLRP6 negatively regulates innate immunity and host defence against bacterial pathogens. Nature 2012, 488:389-393.
7. Armanious H., Gelebart P., Mackey J., Ma Y., Lai R. STAT3 upregulates the protein expression and transcriptional activity of β-catenin in breast cancer. Int. J. Clin. Exp. Pathol. 2010, 3:654-664.
8. Atreya R., Neurath M.F. Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin. Rev. Allergy Immunol. 2005, 28:187-196.
9. Bailey C.E., Hu C.Y., You Y.N., Bednarski B.K., Rodriguez-Bigas M.A., Skibber J.M., Cantor S.B., Chang G.J. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg. 2015, 150:17-22.
10. Becker C., Fantini M.C., Wirtz S., Nikolaev A., Lehr H.A., Galle P.R., Rose-John S., Neurath M.F. IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle 2005, 4:217-220.
11. Ben-Neriah Y., Karin M. Inflammation meets cancer, with NF-κB as the matchmaker. Nat. Immunol. 2011, 12:715-723.
12. Bollrath J., Phesse T.J., von Burstin V.A., Putoczki T., Bennecke M., Bateman T., Nebelsiek T., Lundgren-May T., Canli O., Schwitalla S., et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009, 15:91-102.
13. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337. Cancer Genome Atlas Network.
14. Chen G.Y., Liu M., Wang F., Bertin J., Núñez G. A functional role for Nlrp6 in intestinal inflammation and tumorigenesis. J. Immunol. 2011, 186:7187-7194.
15. Clevers H., Nusse R. Wnt/β-catenin signaling and disease. Cell 2012, 149:1192-1205.
16. Corvinus F.M., Orth C., Moriggl R., Tsareva S.A., Wagner S., Pfitzner E.B., Baus D., Kaufmann R., Huber L.A., Zatloukal K., et al. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia 2005, 7:545-555.
17. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
18. Dauer D.J., Ferraro B., Song L., Yu B., Mora L., Buettner R., Enkemann S., Jove R., Haura E.B. Stat3 regulates genes common to both wound healing and cancer. Oncogene 2005, 24:3397-3408.
19. Dhillon A.S., Hagan S., Rath O., Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007, 26:3279-3290.
20. Ding S., Blue R.E., Morgan D.R., Lund P.K. Comparison of multiple enzyme activatable near-infrared fluorescent molecular probes for detection and quantification of inflammation in murine colitis models. Inflamm. Bowel Dis. 2014, 20:363-377.
21. Ditsworth D., Zong W.X. NF-kappaB: key mediator of inflammation-associated cancer. Cancer Biol. Ther. 2004, 3:1214-1216.
22. Dupaul-Chicoine J., Yeretssian G., Doiron K., Bergstrom K.S., McIntire C.R., LeBlanc P.M., Meunier C., Turbide C., Gros P., Beauchemin N., et al. Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity 2010, 32:367-378.
23. Elinav E., Strowig T., Kau A.L., Henao-Mejia J., Thaiss C.A., Booth C.J., Peaper D.R., Bertin J., Eisenbarth S.C., Gordon J.I., Flavell R.A. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 2011, 145:745-757.
24. Elinav E., Nowarski R., Thaiss C.A., Hu B., Jin C., Flavell R.A. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat. Rev. Cancer 2013, 13:759-771.
25. Fleming M., Ravula S., Tatishchev S.F., Wang H.L. Colorectal carcinoma: Pathologic aspects. J. Gastrointest. Oncol. 2012, 3:153-173.
26. Fodde R., Smits R., Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nat. Rev. Cancer 2001, 1:55-67.
27. Gounaris E., Martin J., Ishihara Y., Khan M.W., Lee G., Sinh P., Chen E.Z., Angarone M., Weissleder R., Khazaie K., Barrett T.A. Fluorescence endoscopy of cathepsin activity discriminates dysplasia from colitis. Inflamm. Bowel Dis. 2013, 19:1339-1345.
28. Greten F.R., Eckmann L., Greten T.F., Park J.M., Li Z.W., Egan L.J., Kagnoff M.F., Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004, 118:285-296.
29. Grivennikov S., Karin E., Terzic J., Mucida D., Yu G.Y., Vallabhapurapu S., Scheller J., Rose-John S., Cheroutre H., Eckmann L., Karin M. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113.
30. Hayden M.S., Ghosh S. NF-κB in immunobiology. Cell Res. 2011, 21:223-244.
31. Heyer J., Yang K., Lipkin M., Edelmann W., Kucherlapati R. Mouse models for colorectal cancer. Oncogene 1999, 18:5325-5333.
32. Hugot J.-P., Chamaillard M., Zouali H., Lesage S., Cézard J.-P., Belaiche J., Almer S., Tysk C., O'Morain C.A., Gassull M., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001, 411:599-603.
33. Hyams J.S., Fitzgerald J.E., Treem W.R., Wyzga N., Kreutzer D.L. Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease. Gastroenterology 1993, 104:1285-1292.
34. Ibrahem S., Al-Ghamdi S., Baloch K., Muhammad B., Fadhil W., Jackson D., Nateri A.S., Ilyas M. STAT3 paradoxically stimulates β-catenin expression but inhibits β-catenin function. Int. J. Exp. Pathol. 2014, 95:392-400.
35. Kang M.J., Yoon C.M., Kim B.H., Lee C.M., Zhou Y., Sauler M., Homer R., Dhamija A., Boffa D., West A.P., et al. Suppression of NLRX1 in chronic obstructive pulmonary disease. J. Clin. Invest. 2015, 125:2458-2462.
36. Kinzler K.W., Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996, 87:159-170.
37. Kuester D., Lippert H., Roessner A., Krueger S. The cathepsin family and their role in colorectal cancer. Pathol. Res. Pract. 2008, 204:491-500.
38. Kurzawski G., Suchy J., Kładny J., Grabowska E., Mierzejewski M., Jakubowska A., Debniak T., Cybulski C., Kowalska E., Szych Z., et al. The NOD2 3020insC mutation and the risk of colorectal cancer. Cancer Res. 2004, 64:1604-1606.
39. Lee H., Herrmann A., Deng J.-H., Kujawski M., Niu G., Li Z., Forman S., Jove R., Pardoll D.M., Yu H. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 2009, 15:283-293.
40. Lee S.H., Hu L.L., Gonzalez-Navajas J., Seo G.S., Shen C., Brick J., Herdman S., Varki N., Corr M., Lee J., Raz E. ERK activation drives intestinal tumorigenesis in Apc(min/+) mice. Nat. Med. 2010, 16:665-670.
41. Lin W.W., Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 2007, 117:1175-1183.
42. Moore C.B., Bergstralh D.T., Duncan J.A., Lei Y., Morrison T.E., Zimmermann A.G., Accavitti-Loper M.A., Madden V.J., Sun L., Ye Z., et al. NLRX1 is a regulator of mitochondrial antiviral immunity. Nature 2008, 451:573-577.
43. Myant K.B., Cammareri P., McGhee E.J., Ridgway R.A., Huels D.J., Cordero J.B., Schwitalla S., Kalna G., Ogg E.L., Athineos D., et al. ROS production and NF-κB activation triggered by RAC1 facilitate WNT-driven intestinal stem cell proliferation and colorectal cancer initiation. Cell Stem Cell 2013, 12:761-773.
44. Neufert C., Becker C., Neurath M.F. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat. Protoc. 2007, 2:1998-2004.
45. O'Shea J.J., Holland S.M., Staudt L.M. JAKs and STATs in immunity, immunodeficiency, and cancer. N. Engl. J. Med. 2013, 368:161-170.
46. Ogura Y., Bonen D.K., Inohara N., Nicolae D.L., Chen F.F., Ramos R., Britton H., Moran T., Karaliuskas R., Duerr R.H., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001, 411:603-606.
47. Rogler G. Chronic ulcerative colitis and colorectal cancer. Cancer Lett. 2014, 345:235-241.
48. Schwitalla S., Fingerle A.A., Cammareri P., Nebelsiek T., Göktuna S.I., Ziegler P.K., Canli O., Heijmans J., Huels D.J., Moreaux G., et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 2013, 152:25-38.
49. Sebolt-Leopold J.S., Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer 2004, 4:937-947.
50. Shaked H., Hofseth L.J., Chumanevich A., Chumanevich A.A., Wang J., Wang Y., Taniguchi K., Guma M., Shenouda S., Clevers H., et al. Chronic epithelial NF-κB activation accelerates APC loss and intestinal tumor initiation through iNOS up-regulation. Proc. Natl. Acad. Sci. USA 2012, 109:14007-14012.
51. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63:11-30.
52. Soares F., Tattoli I., Rahman M.A., Robertson S.J., Belcheva A., Liu D., Streutker C., Winer S., Winer D.A., Martin A., et al. The mitochondrial protein NLRX1 controls the balance between extrinsic and intrinsic apoptosis. J. Biol. Chem. 2014, 289:19317-19330.
53. Staudt L.M. Oncogenic activation of NF-kappaB. Cold Spring Harb. Perspect. Biol. 2010, 2:a000109.
54. Takeuchi O., Akira S. Pattern recognition receptors and inflammation. Cell 2010, 140:805-820.
55. Tattoli I., Carneiro L.A., Jéhanno M., Magalhaes J.G., Shu Y., Philpott D.J., Arnoult D., Girardin S.E. NLRX1 is a mitochondrial NOD-like receptor that amplifies NF-kappaB and JNK pathways by inducing reactive oxygen species production. EMBO Rep. 2008, 9:293-300.
56. Taupin D., Podolsky D.K. Mitogen-activated protein kinase activation regulates intestinal epithelial differentiation. Gastroenterology 1999, 116:1072-1080.
57. Terzić J., Grivennikov S., Karin E., Karin M. Inflammation and colon cancer. Gastroenterology 2010, 138:2101-2114.e5.
58. Thorsteinsdottir S., Gudjonsson T., Nielsen O.H., Vainer B., Seidelin J.B. Pathogenesis and biomarkers of carcinogenesis in ulcerative colitis. Nat. Rev. Gastroenterol. Hepatol. 2011, 8:395-404.
59. Waldner M.J., Foersch S., Neurath M.F. Interleukin-6--a key regulator of colorectal cancer development. Int. J. Biol. Sci. 2012, 8:1248-1253.
60. Wullaert A., Bonnet M.C., Pasparakis M. NF-κB in the regulation of epithelial homeostasis and inflammation. Cell Res. 2011, 21:146-158.
61. Xia X., Cui J., Wang H.Y., Zhu L., Matsueda S., Wang Q., Yang X., Hong J., Songyang Z., Chen Z.J., Wang R.F. NLRX1 negatively regulates TLR-induced NF-κB signaling by targeting TRAF6 and IKK. Immunity 2011, 34:843-853.
62. Yang J., Liao X., Agarwal M.K., Barnes L., Auron P.E., Stark G.R. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev. 2007, 21:1396-1408.
63. Yashiro M. Ulcerative colitis-associated colorectal cancer. World J. Gastroenterol. 2014, 20:16389-16397.
64. Zaki M.H., Boyd K.L., Vogel P., Kastan M.B., Lamkanfi M., Kanneganti T.D. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 2010, 32:379-391.
65. Zaki M.H., Vogel P., Malireddi R.K., Body-Malapel M., Anand P.K., Bertin J., Green D.R., Lamkanfi M., Kanneganti T.D. The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis. Cancer Cell 2011, 20:649-660.